Dr. Timothy F. Lesser, MD
Urology (Urology Physician)
20911 Earl St, Suite 140
Torrance, CA 90503
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Southern California Keck School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,601
Licensed in California since 2005, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Southern California Keck School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
CA license A90955 (first issued 2005; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Torrance Memorial Medical Center Torrance, CA
- Providence Little Company of Mary Med Ctr Torrance Torrance, CA
Medical groups
- Genesis Healthcare PArtners PC (228 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,601
- Services billed
- 29,114
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Leuprolide injectable, camcevi, 1 mg | 1,260 | 23 |
| Automated urinalysis test | 1,117 | 753 |
| Bcg live intravesical instillation, 1 mg | 859 | 12 |
| Established patient office or other outpatient visit, 30-39 minutes | 735 | 581 |
| Ultrasound measurement of bladder capacity after voiding | 733 | 600 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 534 | 143 |
| Established patient office or other outpatient visit, 20-29 minutes | 286 | 260 |
| Complete ultrasound scan behind abdominal cavity | 276 | 251 |
| New patient office or other outpatient visit, 45-59 minutes | 204 | 204 |
| Diagnostic exam of bladder and urethra using an endoscope | 187 | 147 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Torrance, CA | 362 |
| Finasteride Other prescribers in Torrance, CA | 202 |
| Cefdinir Other prescribers in Torrance, CA | 80 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Torrance, CA | 60 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Torrance, CA | 51 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Torrance, CA | 44 |
| Ciprofloxacin Hcl Other prescribers in Torrance, CA | 39 |
| Sildenafil Citrate Other prescribers in Torrance, CA | 35 |
| Gemtesa (vibegron) Other prescribers in Torrance, CA | 35 |
| Dutasteride Other prescribers in Torrance, CA | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 25 companies reported 66 payments worth $1,658 in total to this clinician.
| AbbVie Inc. | $208 |
|---|---|
| Dendreon Pharmaceuticals LLC | $174 |
| Urogen Pharma, Inc. | $152 |
| Janssen Biotech, Inc. | $118 |
| Sumitomo Pharma America, Inc. | $116 |
| Telix Pharmaceuticals | $97.08 |
| Teleflex LLC | $93.27 |
| Bayer HealthCare Pharmaceuticals Inc. | $79.67 |
| Food and Beverage | $1,582 |
|---|---|
| Education | $76.16 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. May 2, 2025 | Education ERLEADA · Oncology · in-kind | $68.00 |
| Urogen Pharma, Inc. Aug 25, 2025 | Education ZUSDURI · LG-IR-NMIBC · in-kind | $8.16 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $94,796 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.